Trends in overall survival and costs of multiple myeloma, 2000–2014

Rafael Fonseca, S. Abouzaid, M. Bonafede, Q. Cai, K. Parikh, L. Cosler, P. Richardson

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients’ outcomes.Leukemia advance online publication, 20 January 2017; doi:10.1038/leu.2016.380.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Jan 20 2017

Fingerprint

Multiple Myeloma
Costs and Cost Analysis
Survival
United States Social Security Administration
Drug Costs
Death Certificates
Proxy
Therapeutics
Health Care Costs
Publications
Leukemia
Databases
Delivery of Health Care
Health
Research

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., & Richardson, P. (Accepted/In press). Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. https://doi.org/10.1038/leu.2016.380

Trends in overall survival and costs of multiple myeloma, 2000–2014. / Fonseca, Rafael; Abouzaid, S.; Bonafede, M.; Cai, Q.; Parikh, K.; Cosler, L.; Richardson, P.

In: Leukemia, 20.01.2017.

Research output: Contribution to journalArticle

Fonseca, R, Abouzaid, S, Bonafede, M, Cai, Q, Parikh, K, Cosler, L & Richardson, P 2017, 'Trends in overall survival and costs of multiple myeloma, 2000–2014', Leukemia. https://doi.org/10.1038/leu.2016.380
Fonseca, Rafael ; Abouzaid, S. ; Bonafede, M. ; Cai, Q. ; Parikh, K. ; Cosler, L. ; Richardson, P. / Trends in overall survival and costs of multiple myeloma, 2000–2014. In: Leukemia. 2017.
@article{d7eae543842a48a1a012a3fc3d5ab86a,
title = "Trends in overall survival and costs of multiple myeloma, 2000–2014",
abstract = "Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7{\%} in 2000 to 61.3{\%} in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3{\%} per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients’ outcomes.Leukemia advance online publication, 20 January 2017; doi:10.1038/leu.2016.380.",
author = "Rafael Fonseca and S. Abouzaid and M. Bonafede and Q. Cai and K. Parikh and L. Cosler and P. Richardson",
year = "2017",
month = "1",
day = "20",
doi = "10.1038/leu.2016.380",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Trends in overall survival and costs of multiple myeloma, 2000–2014

AU - Fonseca, Rafael

AU - Abouzaid, S.

AU - Bonafede, M.

AU - Cai, Q.

AU - Parikh, K.

AU - Cosler, L.

AU - Richardson, P.

PY - 2017/1/20

Y1 - 2017/1/20

N2 - Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients’ outcomes.Leukemia advance online publication, 20 January 2017; doi:10.1038/leu.2016.380.

AB - Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients’ outcomes.Leukemia advance online publication, 20 January 2017; doi:10.1038/leu.2016.380.

UR - http://www.scopus.com/inward/record.url?scp=85009959408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009959408&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.380

DO - 10.1038/leu.2016.380

M3 - Article

C2 - 28008176

AN - SCOPUS:85009959408

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -